Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
Demo Company
PURITAN MEDICAL

Cell Surface Receptor Guides Liver Development

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Identification of a growth factor that directs the differentiation of liver progenitor cells into mature liver cells may pave the way for development of laboratory-grown livers for use in organ transplants that will eliminate the need for living or deceased donors.

Investigators at Mount Sinai School of Medicine (New York, NY, USA) worked with mice and with samples taken from human fetal livers. They discovered that human embryonic stem cells could be differentiated into liver progenitor cells and produce mature liver cells as long at the cells expressed the cell surface growth factor KDR (kinase insert-domain receptor, also known as vascular endothelial growth factor receptor 2).

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. The KDR gene encodes one of the two receptors of VEGF. This receptor, known as kinase insert-domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting. The signaling and trafficking of this receptor are regulated by multiple factors.

The investigators found that the newly differentiated liver cells were fully functional as demonstrated by their ability to be infected by the Hepatitis C virus, a property restricted to liver cells exclusively. KDR-positive progenitor cells were found in both human and mouse liver samples, indicating their importance in the formation of the organ.

"The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said senior author Dr. Valerie Gouon-Evans, assistant professor of developmental and regenerative biology at the Mount Sinai School of Medicine. "Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem."

The study was published in the June 6, 2013, online issue of the journal Cell Stem Cell.

Related Links:

Mount Sinai School of Medicine



Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.